{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-306737","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2026-07-17T11:05:41+00:00","discovered_at":"2026-07-17T11:10:00.346330+00:00","generated_at":"2026-07-17T11:10:06.162715+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kalaris reports positive expanded Phase 1a data for TH103 in nAMD; 29% no retreatment in 6 months","bullets":["Expanded Phase 1a SAD dataset: 17 treatment-naïve + 3 treatment-experienced patients; all 20 completed 6-month follow-up.","After single TH103 injection, 41% of treatment-naïve patients retreatment at ≥4 months, 29% no anti-VEGF treatment in 6 months.","Mean 9.2-letter BCVA improvement, 118µm CST reduction, 93% reduction in intraretinal fluid at one month.","TH103 plasma Cmax 27- to 53-fold lower vs leading anti-VEGF agents on molar equivalence basis.","No IOI at 2.5 mg with improved manufacturing; Phase 1b/2 enrolling, initial data expected 1H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-306737","json":"https://secwatch.observer/filing/0001193125-26-306737.json","markdown":"https://secwatch.observer/filing/0001193125-26-306737.md","text":"https://secwatch.observer/filing/0001193125-26-306737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/0001193125-26-306737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/d125006d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-17T11:10:06.162715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}